Five Research Collaborations: Myriad Genetics Investigates MRD Tests in Breast Cancer

Myriad Genetics, a leading company in the field of genetic testing and precision medicine solutions, announced a series of research collaborations to investigate the use of molecular residual disease (MRD) testing in breast cancer. These studies utilize Myriad's Precise® MRD test to gain new insights. A central goal of this collaboration is to explore whether the level of circulating tumor DNA (ctDNA) can predict the strength of the response to therapy with Pembrolizumab and hormonal treatments in breast cancer patients. These innovative research projects promise not only deeper insights into the effectiveness of therapies but also an advanced approach to personalized cancer treatment. Combined with Myriad's expertise, MRD testing could become key to more accurate and individualized therapy planning. As a pioneer in precision medicine research, Myriad Genetics emphasizes once again, through these partnerships, its commitment to advancing science for the benefit of patients. The possibilities being explored could set new standards in breast cancer treatment and bring personalized healthcare closer.